Genor Biopharma and BIOCND partner to develop Biosimilar copies of Humira and Herceptin

Genor Biopharma Co. Ltd and BIOCND Inc, a Korean biotech company, have partnered to develop two mAb biosimilars for international markets.  According to the signed agreement, Genor Biopharma licensed out to BIOCND the South Asia, Southeast and Northeast Asia (except Greater China), and Russia right of GB232 (a Adalimumab biosimilar), and ROW (except Greater China, Japan, the United States, and Europe) right of GB221 (a Trastuzumab biosimilar).